Abstracts Archive - Page 36 of 2425 - ACR Meeting Abstracts

Abstract Number: 0262 • ACR Convergence 2024
Bartonella Endocarditis as an Important Mimic of ANCA Associated Vasculitis: Results of a Large Single Center Descriptive Analysis
Adam Brown¹, Adil Vural², Cassandra Calabrese³ and Leonard Calabrese², ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic Foundation, Cleveland Heights, OH
Background/Purpose: Infective Endocarditis (IE) is an important mimic of numerous forms of systemic vasculitis and especially Anti-Neutrophilic Cytoplasmic Antibody vasculitis (AAV). Bartonella endocarditis (BE) is…
Abstract Number: 0259 • ACR Convergence 2024
Whipple’s Disease in Patients Initially Diagnosed with Rheumatic Diseases: A Case Series
Judith den Hertog¹, Maike Wientjes¹, Jaap ten Oever², Merel Opdam¹, Denise Telgt¹ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Radboudumc, Nijmegen, Netherlands
Background/Purpose: Whipple’s disease is a presumably rare, chronic infectious disease caused by the bacterium Tropheryma whipplei. Symptoms include weight loss, diarrhea, abdominal discomfort, joint pain…
Abstract Number: 0243 • ACR Convergence 2024
Humoral Response to SARS-CoV-2 Vaccination and Breakthrough COVID-19 Disease in Patients with Immune-mediated Inflammatory Diseases Receiving Biological Treatment
Eve-Kai Raussi, Maigi Eisen, Küllike Palk and Marge Kütt, North Estonia Medical Centre Foundation, Tallinn, Estonia
Background/Purpose: Immune response in patients with immune-mediated inflammatory diseases (IMID) is compromised. As SARS-CoV-2 vaccine trials excluded patients on immunosuppressive therapy, data about vaccination efficacy…
Abstract Number: 0263 • ACR Convergence 2024
Characteristics and Coinfections of Diffuse Alveolar Hemorrhage in Rheumatic Patients
Eduardo Briones-García¹, Shaul Navarro-Lara², Marco A Ortiz-Bustamante², Iris Paola García Herrera³, Carla M Roman-Montes² and Guillermo A Guaracha-Basañez⁴, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department., Ciudad de México, Distrito Federal, Mexico, ²Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador-Zubirán., México city, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion “Salvador Zubirán”, Mexico City, Distrito Federal, Mexico
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a severe respiratory complication observed in certain rheumatic diseases, such as systemic lupus erythematosus (SLE), ANCA-associated vasculitides (AAV), and…
Abstract Number: 0148 • ACR Convergence 2024
The Incidence and Prevalence of Sarcoidosis in England
Katie Bechman¹, Kathryn Biddle¹, Mark Russell², Mark Gibson¹, maryam adas¹, Zijing Yang², Edward Alveyn¹, deepak Nagra², Sam Norton², Surinder biring¹ and James Galloway³, ¹King's College London, London, United Kingdom, ²King's College London, London, England, United Kingdom, ³Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Sarcoidosis is heterogeneous condition, ranging from mild self-limiting disease to severe organ involvement and death. Despite its clinical significance, the epidemiological landscape in England…
Abstract Number: 0145 • ACR Convergence 2024
Community Mobility in a Diverse Cohort of Individuals with Systemic Lupus Erythematosus
Leila Milanfar¹, Jinoos Yazdany², Amanda Eudy³, Courtney Hoge⁴, Charmayne M. Dunlop-Thomas⁵, Patti Katz⁶ and Laura Plantinga⁷, ¹University of California San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³Duke University, Raleigh, NC, ⁴Emory University, Atlanta, GA, ⁵Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁶UCSF, San Rafael, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Measurement of the extent to which individuals move throughout their community and participate in social activities (“community mobility”) can provide a snapshot of how…
Abstract Number: 0223 • ACR Convergence 2024
A Comparative Study of Difficult-to-Treat vs Non-Difficult-to-Treat Psoriatic Arthritis for Disease Burden and Comorbidities: An Ultrasound Study
Ricardo Sabido-Sauri¹, Seyyid Bilal Acikgoz², Ozun Bayindir Tsechelidis³, Ummugulsum Gazel¹, Sylvia Sangwa⁴, Elliot Hepworth¹ and Sibel Aydin⁵, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: In the era of several advanced therapies and an increased number of patients with psoriatic arthritis (PsA) who have been failed by multiple treatment…
Abstract Number: 0231 • ACR Convergence 2024
Imaging Characteristics and Demographic Variations in Patients with Axial Spondylarthritis, Axial Psoriatic Arthritis, and Inflammatory Bowel Disease-Related Arthritis with Axial Involvement: Insights from a Single Center at Cleveland Clinic Abu Dhabi
Rajaie Namas¹, Ahlam Almarzooqi², Sarah Al Qassimi³ and Esat Memisoglu³, ¹Cleveland Clinic Abu Dhabi, Detroit, MI, ²Emirates Health Services, Sharjah, United Arab Emirates, ³Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Background/Purpose: Spondyloarthropathies (SpAs) are a group of seronegative, inflammatory arthritides, including axial spondylarthritis (ax-SpA), axial psoriatic arthritis (ax-PsA), and inflammatory bowel disease related arthritis with…
Abstract Number: 0241 • ACR Convergence 2024
Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients
Rebecca Sadun¹, Dan Crair¹, Emmanuel Walter¹, Eugene St.Clair², David Pisetsky², Amanda Eudy³, Megan Clowse⁴, Jennifer Rogers⁵, Kai Sun¹, Lisa Criscione-Schreiber⁶, Mithu Maheswaranathan⁶, Jayanth Doss¹, Sarah Valencia¹ and M. Athony Moody⁷, ¹Duke University, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Duke University, Raleigh, NC, ⁴Duke University, Chapel Hill, NC, ⁵Duke, Durham, NC, ⁶Duke University School of Medicine, Durham, NC, ⁷Duke University School of Medicine, Durham
Background/Purpose: The ACR recommends SARS-CoV-2 vaccination for all patients with rheumatic diseases, but it is unknown how patients with SLE will respond to the vaccine,…
Abstract Number: 0228 • ACR Convergence 2024
Do Imaging Tests Have a Role in Predicting Progression to Rheumatoid Arthritis in People with Clinically Suspect Arthralgia? A Systematic Review & Meta-Analysis
Ankita Gupta¹, Sulaiman Anis² and Paola de Pablo², ¹Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Clinically suspect arthralgia (CSA) has been associated with an increased risk of developing inflammatory arthritis (IA). Subclinical inflammation on imaging tests may help to…
Abstract Number: 0295 • ACR Convergence 2024
Mycophenolate Mofetil in the Treatment of Patients with Isolated Cardiac Sarcoidosis
Namitha Nair¹, Leen Al Saleh², Haya Haddad³, Maria Jaimes Reyes⁴, Vishakha Chetram⁵, Farooq Sheikh⁶, FLORINA CONSTANTINESCU⁷ and Anjani Pillarisetty⁸, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Watson Clinic, Lakeland, FL, ³Medstar Washington Hospital Center, Silver Spring, MD, ⁴Medstar Washington Hospital Center/Georgetown University, Washington, DC, ⁵Inova Schar Heart and Vascular, Falls Chirch, VA, ⁶MedStar Heart and Vascular Institute, Georgetown University School of Medicine, Washington, DC, ⁷MedStar Washington Hospital Center, Washington, DC, ⁸Carson Tahoe Medical Group, Reno, NV
Background/Purpose: Cardiac involvement is seen in approximately a fourth of patients with sarcoidosis, a non-necrotizing granulomatous systemic disease. Among these patients, 25% may have isolated cardiac…
Abstract Number: 0237 • ACR Convergence 2024
Tofacitinib: A Retrospective Study on Safety and Adverse Effects
Vrushal Kale¹, Sandeep yadav², Canchi Balakrishnan³, Rohini Samant⁴, Bishakha Swain⁴, Shaurav Khanna⁵, Aashish Agrawal⁵ and Aditi Patankar⁴, ¹P D Hinduja national Hospital and medical Research centre, Mumbai, Maharashtra, India, ²Pd Hinduja hospital, Thane, Maharashtra, India, ³P D Hinduja Hospital and Medical Research Centre, Mahim, Mumbai, Mahin, Maharashtra, India, ⁴P D Hinduja Hospital and Medical Research Centre, Mumbai, mumbai, Maharashtra, India, ⁵P D Hinduja Hospital and Medical Research Centre, Mahim, Mumbai, Mumbai, Maharashtra, India
Background/Purpose: Tofacitinib, an oral Janus kinase inhibitor, is widely used in India to treat rheumatoid arthritis (RA) and other autoimmune diseases. Although its efficacy is…
Abstract Number: 0304 • ACR Convergence 2024
Severe Infection in COVID-19 Vaccinated Patients with Systemic Autoimmune Rheumatic Diseases on B Cell Targeted Therapies: Association with Neutrophil-lymphocyte Ratio
doryan Garcia Olivas¹, Judith Hernández Sánchez¹, luis Bausá Gimeno¹, Javier Nóvoa Medina¹, Sergio Machín¹, Maria Ángeles Acosta-Mérida¹, Diana Botello-Corzo¹, daniel Batista Perdomo¹, José Ángel Hernández Beriain² and Beatriz Tejera Segura¹, ¹Rheumatology Department. Hospital Universitario Insular de Gran Canaria, las Palmas, Spain, ²Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARDs) are at higher risk of general infection due to the presence of comorbidities, underlying disease activity, and…
Abstract Number: 0291 • ACR Convergence 2024
Safety of Biologic Therapy in Kidney Transplant Recipients with Inflammatory Diseases: Real-world Experience from a Tertiary Medical Center
Victoria Furer¹, Omer Kersh², Mark Berman³, Ayelet Grupper² and Ori Elkayam⁴, ¹Tel Aviv Medical Center, Tel Aviv, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Tel Aviv, Israel, ³Tel Aviv Sourasky Medical Center, Kefar sava, Israel, ⁴Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Management of solid-organ transplant (SOT) recipients with systemic inflammatory diseases represents a clinical challenge in the paucity of data related to the safety of…
Abstract Number: 0254 • ACR Convergence 2024
Rheumatic Manifestations in Patients with Hansen’s Disease Treated with Multidrug Antibiotic Therapy
Pedro Gil De Rubio Cruz¹, Andrea Lastra-Annexy², Natalia Pelet Del Toro¹, Luis Vilá¹ and Aida Quintero-Noriega¹, ¹University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²Universidad Central del Caribe School of Medicine, Bayamón, PR
Background/Purpose: Hansen’s Disease (HD), also known as leprosy, is a chronic granulomatous infection caused by Mycobacterium leprae. A wide range of rheumatic manifestations has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].